pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

6,918 products tracked · 1,831 matching

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health
viewlistcards
Marketed
pembrolizumab
Keytruda (pembrolizumab)
Merkel Cell Carcinoma
Programmed cell death protein 1
$MRKMerck & Co., Inc.
125 catalysts
Marketed
nivolumab
Opdivo (nivolumab)
Colorectal Cancer
Programmed cell death protein 1
Bristol-Myers Squibb Co
86 catalysts
Marketed
atezolizumab
Tecentriq (atezolizumab)
Muscle Invasive Bladder Cancer (MIBC)
← prev
page 1 of 62
next →
131
Pain89
Neurology1
Programmed cell death 1 ligand 1
F. Hoffmann-La Roche Ltd
41 catalysts
Marketed
MEDROL
MEDROL (METHYLPREDNISOLONE)
Glucocorticoid receptor
$PFEPFIZER INC
34 catalysts
Marketed
blinatumomab
Blincyto (blinatumomab)
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
B-lymphocyte antigen CD19T cell surface glycoprotein CD3
$AMGNAMGEN INC
25 catalysts
Marketed
cabozantinib s-malate
Cometriq (cabozantinib s-malate)
Endometrial Cancer
Hepatocyte growth factor receptorVascular endothelial growth factor receptor 2
$EXELEXELIXIS, INC.
25 catalysts
Marketed
venetoclax
Venclexta (venetoclax)
Mantle Cell Lymphoma
Apoptosis regulator Bcl-2
$ABBVAbbVie Inc.
22 catalysts
Marketed
cemiplimab
Libtayo (cemiplimab-rwlc)
Melanoma
Programmed cell death protein 1
$REGNREGENERON PHARMACEUTICALS, INC.
17 catalysts
Marketed
CALQUENCE
CALQUENCE (ACALABRUTINIB)
Tyrosine-protein kinase BTK
$AZNASTRAZENECA PLC
13 catalysts
Marketed
asciminib hydrochloride
Scemblix (asciminib hydrochloride)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
$NVSNOVARTIS AG
13 catalysts
Marketed
dexamethasone
Hemady (dexamethasone [INN])
Multiple Myeloma (Kahler Disease)
Fera Pharmaceuticals LLC
10 catalysts
Marketed
Maxtrex
Methotrexate Sodium (methotrexate)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
$PFEPFIZER INC
8 catalysts
Phase 3
bevacizumab
Avastin (bevacizumab)
Melanoma
Vascular endothelial growth factor A, long form
F. Hoffmann-La Roche Ltd
5 catalysts
Marketed
capivasertib
Truqap (capivasertib)
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast…
Serine/threonine-protein kinase AKT
$AZNASTRAZENECA PLC
5 catalysts
Marketed
capecitabine
Capecitabine (capecitabine)
Colon Cancer
Armas Pharmaceuticals Inc
3 catalysts
Marketed
cyclophosphamide
Cyclophosphamide (cyclophosphamide [INN])
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Long Grove Pharmaceuticals LLC
3 catalysts
Marketed
Carboplatin Pfizer
Carboplatin (carboplatin)
Metastatic Ovarian Cancer
$PFEPFIZER INC
2 catalysts
Marketed
DASATINIB
DASATINIB (DASATINIB)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Bcr/Abl fusion protein
Xspray Pharma AB
2 catalysts
Marketed
Onureg
Onureg (azacitidine)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Bristol-Myers Squibb Co
2 catalysts
Marketed
ipilimumab
Yervoy (ipilimumab)
Esophageal Squamous Cell Carcinoma (ESCC)
Bristol-Myers Squibb Co
2 catalysts
Phase 1
CK-0804
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Cellenkos Inc
1 catalysts
Phase 2
ONO-4578
Metastatic Colorectal Cancer
Bristol-Myers Squibb Co
1 catalysts
Marketed
avelumab
Bavencio (avelumab)
Merkel Cell Carcinoma
EMD Serono Inc
1 catalysts
Phase 2
brentuximab vedotin
Adcetris (brentuximab vedotin)
Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
TubulinTumor necrosis factor receptor superfamily member 8
$PFEPFIZER INC
1 catalysts
Phase 2
cadonilimab
Hepatocellular Carcinoma
Programmed cell death protein 1Cytotoxic T-lymphocyte protein 4
Akeso Inc
1 catalysts
pre_registration
camizestrant
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast…
Estrogen receptor
$AZNASTRAZENECA PLC
1 catalysts
Marketed
ceritinib
Zykadia (ceritinib)
Non-Small Cell Lung Cancer
$NVSNOVARTIS AG
1 catalysts
Phase 3
cisplatin
Hyalcis (cisplatin)
Lip Cancer
Privo Technologies Inc
1 catalysts
Phase 3
daraxonrasib
Non-Small Cell Lung Cancer
$RVMDRevolution Medicines, Inc.
1 catalysts
Phase 2
emavusertib hydrochloride
Chronic Lymphocytic Leukemia (CLL)
$CRISCURIS INC
1 catalysts